DARKPOOL0.1.0
AFT-MKT Sign in
RAPP
Rapport Therapeutics, Inc.
NGM Equity
27.02
+1.06 (+4.08%)
52w low 22.06 52.93 high
16.1% of range
Open
26.06
High
27.10
Low
25.77
Prev Close
25.96
Volume
626.29K
Avg Vol 3M
752.15K
Market Cap
1.60B
Currency
USD

6 Month Trend

full chart ›
— C-- Chg-- Gap-- Vol-- ×avg-- σ-- SMA20-- SMA50-- SMA200-- RSI-- SPY-- DD-- Bench-- Sig-- Hist-- hover · click to pin · ← → step · drag to zoom · shift-drag to measure
30.0040.0050.00May 26Jun 26Jul 26Aug 26Sep 26Nov 26
—Context
  • Move across the chart.

Company

SectorHealthcare
IndustryBiotechnology
CountryUnited States
Employees84
Website ↗

Performance

change over each horizon
1D +4.08%
5D +4.20%
1M -10.38%
3M -43.39%
6M -29.04%
YTD -10.94%
1Y +5.96%
2Y +0.45%
3Y --
5Y --
MAX +16.17%

Technical Rating

990 daily bars
Sell
1 bullish 4 bearish 1 neutral
SignalReading
− Price vs 50-day average 27.02 vs 29.21
− Price vs 200-day average 27.02 vs 39.33
− 50-day vs 200-day 29.21 vs 39.33
+ MACD histogram +0.410
− 3-month rate of change -34.7%
· RSI (14) 50.0 (neutral)

A mechanical summary of past prices only — six indicators, one vote each. It uses no fundamentals, no news and no knowledge of your circumstances, and the signals disagree by design. Not investment advice.

ML Prediction

990 daily bars
BUY
SignalReading
Predicted next close 27.89
Predicted change +3.22%
Trend UP
Support / Resistance 22.69 / 29.21
Track record 100% of 1 provisional
  • model: +3.2%
  • uptrend confirmed

A mechanical fit to past prices, nothing more — no fundamentals, no news, no view of your circumstances. Historically close to a coin flip on direction (see the backtest). Not investment advice.

Valuation

P/E Trailing--
P/E Forward-6.26x
Price / Book3.19x
Price / Sales76.94x
EV / EBITDA-6.92x
EPS Trailing-3.17
Dividend Yield0.00%
Beta1.40

Profitability

Gross Margin-149.40%
Operating Margin-838.08%
Net Margin0.00%
Return on Equity-33.33%
Return on Assets-21.96%
Revenue Growth--
Debt / Equity0.02x
Current Ratio20.07x

Business

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Keys & commands

/focus the command box
AAPL Enteropen a ticker
apple Entersearch by company name (suggestions drop down as you type)
AAPL GPopen a ticker on a screen: DES, GP, FA
W PORT HZNwatchlist, portfolio, horizon
1–5DES, GP, W, FA, PORT for the current symbol
↑ ↓ Escmove through suggestions, close
?this reference

On a chart: hover for the readout, click to pin, drag to zoom, shift-drag to measure.